

# Hadar Goldvaser

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6968495/publications.pdf>

Version: 2024-02-01

66  
papers

818  
citations

623734

14  
h-index

552781

26  
g-index

68  
all docs

68  
docs citations

68  
times ranked

1310  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecularly Confirmed Female Donor-Transmitted Lobular Breast Cancer to Male following Renal Transplantation. <i>Pathobiology</i> , 2023, 90, 63-68.	3.8	3
2	Abstract P2-11-16: Rate of breast biopsy referrals in <i>BRCA</i> mutation carriers: A retrospective comparative study and matched analysis. <i>Cancer Research</i> , 2022, 82, P2-11-16-P2-11-16.	0.9	0
3	Germline Pathogenic Variants in <i>BRCA1</i> and <i>BRCA2</i> : Malignancies Beyond Female Breast and Ovarian Cancers. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200003.	1.6	0
4	Rate of breast biopsy referrals in female <i>BRCA</i> mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis. <i>Breast Cancer Research and Treatment</i> , 2022, , 1.	2.5	0
5	Recurrence Score (RS) results, clinicopathologic characteristics, treatments, and outcomes in primary versus subsequent breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry.. <i>Journal of Clinical Oncology</i> , 2022, 40, 565-565.	1.6	0
6	Incidence of lung cancer following pneumonia in smokers: a population-based study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, , .	0.5	2
7	Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3369-3379.	2.5	21
8	Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 379-387.	2.5	3
9	COVID-19 in a patient receiving adjuvant breast cancer chemotherapy with granulocyte colony-stimulating factor (G-CSF) support: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 14, 117.	1.0	1
10	Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade. <i>Scientific Reports</i> , 2021, 11, 10843.	3.3	1
11	The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1086-1086.	1.6	0
12	Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6571-6571.	1.6	0
13	Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?. <i>Medicine (United States)</i> , 2021, 100, e26388.	1.0	8
14	Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2415-2418.	3.0	7
15	Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis. <i>Breast</i> , 2021, 58, 173-181.	2.2	23
16	The impact of endogenous estrogen exposures on the characteristics and outcomes of estrogen receptor positive, early breast cancer. <i>Discover Oncology</i> , 2021, 12, 26.	2.1	2
17	The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer. <i>Oncology</i> , 2021, 99, 713-721.	1.9	0
18	The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 100, 102293.	7.7	3

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. <i>Breast</i> , 2021, 60, 62-69.	2.2	88
20	Response to Soran et al.. <i>Breast</i> , 2021, 60, 306-307.	2.2	0
21	Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. <i>Annals of Hematology</i> , 2021, 100, 2879-2887.	1.8	3
22	Efficacy of immune checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2020, 9, 7613-7625.	2.8	12
23	Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors. <i>Cancer Medicine</i> , 2020, 9, 7888-7895.	2.8	5
24	National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study. <i>Cancer Treatment Reviews</i> , 2020, 91, 102113.	7.7	4
25	The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer. <i>Cancer Medicine</i> , 2020, 9, 4603-4612.	2.8	3
26	Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 259-266.	2.5	0
27	Fractionation scheme and treatment planning method for early glottic cancer in the United States: Economic impact of different medical decisions. <i>Head and Neck</i> , 2020, 42, 1713-1720.	2.0	3
28	The impact of exogenous estrogen exposure on the characteristics of estrogen receptor (ER) positive, early-stage breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e12606-e12606.	1.6	0
29	Efficacy of immune check point inhibitors (ICIs) in metastatic gastric or gastroesophageal junction (GEJ) cancer by patient subgroups: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16587-e16587.	1.6	0
30	Associations between safety and tolerability and reporting of health-related quality of life in phase III randomized trials in common solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19206-e19206.	1.6	0
31	The impact of endogenous estrogen exposure on the characteristics of estrogen receptor (ER) positive, early-stage breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e12605-e12605.	1.6	0
32	NIMG-06. GUILLAIN BARRE MIMICKING LEPTOMENINGEAL SPREAD IN CANCER PATIENTS: REPORT OF TWO CASES AN REVIEW OF LITERATURE. <i>Neuro-Oncology</i> , 2020, 22, ii147-ii148.	1.2	0
33	Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz033.	2.9	20
34	Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock. <i>JACC: CardioOncology</i> , 2019, 1, 141-144.	4.0	8
35	Role of Bisphosphonates in Breast Cancer Therapy. <i>Current Treatment Options in Oncology</i> , 2019, 20, 26.	3.0	43
36	Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 531-545.	2.5	42

#	ARTICLE	IF	CITATIONS
37	Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials. Mayo Clinic Proceedings, 2019, 94, 74-83.	3.0	10
38	Assessment of Frequency and Reporting of Changes in Cancer Trial Design After Initiation of Patient Accrual. JAMA Oncology, 2019, 5, 107.	7.1	2
39	Prognostic Value of the Detection of Lymphovascular Invasion in Hormone Receptor-Positive Early Breast Cancer in the Era of Molecular Profiling. Oncology, 2019, 96, 14-24.	1.9	10
40	De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.. Journal of Clinical Oncology, 2019, 37, 524-524.	1.6	0
41	Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. Breast Cancer Research and Treatment, 2018, 169, 413-425.	2.5	14
42	Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 31-39.	6.3	129
43	Comparison of published and unpublished phase I clinical cancer trials: an analysis of the ClinicalTrials.gov database. Investigational New Drugs, 2018, 36, 933-938.	2.6	10
44	Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials. Journal of Clinical Oncology, 2018, 36, 1798-1804.	1.6	27
45	Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis. Cancer Treatment Reviews, 2018, 71, 68-75.	7.7	9
46	Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. Cancer Treatment Reviews, 2018, 70, 138-143.	7.7	9
47	Screening for occult cancer in idiopathic venous thromboembolism " Systemic review and meta-analysis. European Journal of Internal Medicine, 2017, 42, 74-80.	2.2	9
48	Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. Cancer Treatment Reviews, 2017, 60, 53-59.	7.7	21
49	Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer. Cancer Treatment Reviews, 2017, 59, 46-53.	7.7	2
50	Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications. Investigational New Drugs, 2017, 35, 827-833.	2.6	9
51	Characterisation of blood-derived exosomal hTERT mRNA secretion in cancer patients: a potential pan-cancer marker. British Journal of Cancer, 2017, 117, 353-357.	6.4	38
52	The association between smoking and breast cancer characteristics and outcome. BMC Cancer, 2017, 17, 624.	2.6	25
53	Toxicity of extended adjuvant aromatase inhibitors therapy in postmenopausal breast cancer patients: A systemic review and meta-analysis.. Journal of Clinical Oncology, 2017, 35, 549-549.	1.6	1
54	Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity. World Journal of Gastroenterology, 2017, 23, 1387.	3.3	14

#	ARTICLE	IF	CITATIONS
55	Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity.. Journal of Clinical Oncology, 2017, 35, 552-552.	1.6	0
56	Tumor cells derived exosomes contain hTERT mRNA and transform nonmalignant fibroblasts into telomerase positive cells. Oncotarget, 2016, 7, 59173-59188.	1.8	93
57	The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics. International Journal of Endocrinology, 2016, 2016, 1-9.	1.5	5
58	Perception of prognosis of cancer patients by non-oncologists. International Journal of Clinical Practice, 2016, 70, 1027-1032.	1.7	9
59	Malignancy associated SIADH: Characterization and clinical implications. Acta Oncologica, 2016, 55, 1190-1195.	1.8	20
60	Colorectal cancer in young patients: is it a distinct clinical entity?. International Journal of Clinical Oncology, 2016, 21, 684-695.	2.2	35
61	High Lung Cancer Incidence in Heavy Smokers Following Hospitalization due to Pneumonia. American Journal of Medicine, 2016, 129, 332-338.	1.5	4
62	The association between antihypertensive medications and breast cancer characteristics.. Journal of Clinical Oncology, 2016, 34, e12000-e12000.	1.6	0
63	Malignancy associated SIADH: Characterization and clinical implications.. Journal of Clinical Oncology, 2016, 34, e21622-e21622.	1.6	0
64	The association between treatment for metabolic disorders and breast cancer characteristics.. Journal of Clinical Oncology, 2016, 34, 527-527.	1.6	1
65	Colorectal cancer in young patients: Is it a distinct clinical entity?. Journal of Clinical Oncology, 2015, 33, e14594-e14594.	1.6	0
66	Adjuvant Docetaxel and Cyclophosphamide (DC) with Prophylactic Granulocyte Colony-Stimulating Factor (G-CSF) on Days 8 & 12 in Breast Cancer Patients: A Retrospective Analysis. PLoS ONE, 2014, 9, e107273.	2.5	7